Skip header and navigation

1 records – page 1 of 1.

Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
Clin Lab Haematol. 2006 Feb;28(1):30-5
Publication Type
Saka B.
Aktan M.
Sami U.
Oner D.
Sanem O.
Dinçol G.
Author Affiliation
Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Clin Lab Haematol. 2006 Feb;28(1):30-5
Publication Type
Aged, 80 and over
Antigens, CD38 - blood
Bone Marrow Neoplasms - blood - diagnosis - mortality - secondary
Disease-Free Survival
Enzyme-Linked Immunosorbent Assay - methods
Follow-Up Studies
Leukemia, B-Cell, Chronic - blood - diagnosis - mortality
Middle Aged
Predictive value of tests
Prospective Studies
Receptors, IgE - blood
Tumor Markers, Biological - blood
ZAP-70 Protein-Tyrosine Kinase - blood
Soluble CD23 (sCD23) was proposed as a marker of disease activity and as an important prognostic parameter in B-cell chronic lymphocytic leukemia (B-CLL). In this study, prognostic significance of sCD23 in B-CLL was examined according to its temporal relationship with the known clinical parameters of the disease, CD38 and ZAP-70. Serum sCD23 levels of 36 B-CLL patients, followed up in our clinic between 1999 and 2005, and 15 healthy subjects were measured with enzyme-linked immunosorbent assay. The mean serum sCD23 level of the B-CLL patients (210.72 +/- 193.67 and 6-600 U/ml) was significantly higher than the control group (18.20 +/- 14.30 and 6-50 U/ml). Seventy-eight percent of the B-CLL patients with lymphocyte doubling time (LDT) 12 months had high sCD23 levels (P = 0.008). Meanwhile, 81% of the patients with diffuse bone marrow infiltration and 33% of patients with nondiffuse infiltration had high levels of serum sCD23 (P = 0.029). A significant difference was found between B-CLL patients with Binet stages A and C (P = 0.009). Peripheral blood flow cytometry of the patients revealed a significant CD38 expression in patients with high serum sCD23 levels (P = 0.002). Similarly, an increased bone marrow zeta-chain associated protein kinase-70 (ZAP-70) expression was seen in patients with high serum sCD23 levels (P = 0.009, correlation co-efficient was 0.714). Cumulative and the progression free survivals of the patients with low serum sCD23 levels were 60.1 +/- 5.7 months [95% confidence interval (CI); 49.0-71.2] and 51.1 +/- 6.6 months (95% CI; 38.0-64.1), respectively. However, they were 43.8 +/- 6.5 months (95% CI; 31.0-56.6) and 26.5 +/- 6.4 months (95% CI; 14.0-39.1) in patients with high levels. Serum sCD23 is increased in B-CLL patients and can be used in the clinical follow-up of the disease in prediction of the tumor mass and prognosis.
PubMed ID
16430457 View in PubMed
Less detail